retatrutide eli lilly press release 2024 2025 Obesity Wins Recast And Foundayo As Cardiometabolic Story Eli Lilly touts new weight-loss
Description
Phase 2 SYNERGY-NASH data showed significant reductions in liver fat fraction and NASH resolution rates
It works well as a gentle breakfast or a lightly sweet meal later in the day
Research continues to examine how treatment duration and medication dose affect eye complication rates
The only online sources are research-use-only suppliers, and the only clinical route is an active trial listed on ClinicalTrials.gov
So, if someone gained weight and then started taking GLP-1 agonist medications, the end result result may not be exactly what that person looked like previously
